Clopidogrel is an antiplatelet agent used to prevent blood clots in peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.
- Mechanism
- Curator reviewed · 3 references
Clopidogrel is activated via a 2 steps reaction to an active thiol-containing metabolite. This active form is a platelet inhibitor that irreversibly binds to P2Y12 ADP receptors on platelets. This binding prevents ADP binding to P2Y12 receptors, activation of the glycoprotein GPIIb/IIIa complex, and platelet aggregation.
- Primary indication
- Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,Curator reviewed · 9 structured indications
- Formula / weight
- C16H16ClNO2S · 321.822 g/mol (avg)
- First approval
- Canada, 2006 · United States, 1900 · European Union, 2016
- Code names
- R-130964 · SR-25990
- Brand names
Resolves to
GKTWGGQPFAXNFI-HNNXBMFYSA-NSMILES[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1ClWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Clopidogrel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account